BPG is committed to discovery and dissemination of knowledge
Opinion Review
Copyright: ©Author(s) 2026.
World J Gastrointest Oncol. Sep 15, 2026; 18(9): 118614
Published online Sep 15, 2026. doi: 10.4251/wjgo.118614
Figure 1
Figure 1 Multidimensional framework for prognostic prediction in human epidermal growth factor receptor-2-negative advanced gastric cancer undergoing immunochemotherapy. PD-L1: Programmed cell death ligand 1; MSI: Microsatellite instability; MMR: Mismatch repair; EBV: Epstein-Barr virus; ctDNA: Circulating tumor DNA; TNM: Tumor-node-metastasis; ECOG: Eastern Cooperative Oncology Group; NLR: Neutrophil-to-lymphocyte ratio; PLR: Platelet-to-lymphocyte ratio; LMR: Lymphocyte-to-monocyte ratio; PNI: Prognostic nutritional index; CALLY: C-reactive protein-albumin-lymphocyte; CRP: C-reactive protein; PD-1: Programmed cell death protein 1; AI: Artificial intelligence.
Figure 2
Figure 2 Current challenges and future directions of prognostic modeling in immunochemotherapy for advanced gastric cancer. PD-L1: Programmed cell death ligand 1; IHC: Immunohistochemistry; AI: Artificial intelligence; ctDNA: Circulating tumor DNA; ML: Machine learning.


Write to the Help Desk